Corpus Intelligence IC Memo — BHMC-CONWAY 2026-04-26 04:02 UTC
IC Memo — BHMC-CONWAY
Investment Committee Memorandum | AR | 108 beds | Grade C | EBITDA uplift $7.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BHMC-CONWAY

CCN 040154 | FAULKNER, AR | 108 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BHMC-CONWAY is a 108-bed under-performing / distressed in FAULKNER, AR with $94.7M in net patient revenue and a -15.6% operating margin. The hospital serves a payer mix of 40.3% Medicare, 8.6% Medicaid, and 51.1% commercial.

Thesis: Undervalued. Our ML models identify $7.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -15.6% to -8.2% (+736bps).

Net Revenue HCRIS$94.7M
Current EBITDA COMPUTED$-14.8M
Operating Margin COMPUTED-15.6%
Occupancy HCRIS45.6%
Revenue / Bed COMPUTED$877K
Net-to-Gross HCRIS23.3%
Distress Probability ML50.6%

2. Market Context & Competitive Position

108
AR Hospitals
-7.6%
State Median Margin
31
Comparable Hospitals

AR has 108 Medicare-certified hospitals with a median operating margin of -7.6%. The target's margin of -15.6% places it below the state median. Among 31 size-comparable peers (54-216 beds), the median margin is 1.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (54-216), prioritizing same-state peers. 31 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BHMC-CONWAY (Target)AR108$94.7M-15.6%
BAXTER REGIONAL MEDICAL CENTERAR169$282.2M-2.8%
BAPTIST HEALTH MEDICAL CENTER-AR200$278.0M0.2%
WHITE COUNTY MEDICAL CENTERAR179$251.3M3.4%
WHITE RIVER MEDICAL CENTERAR170$247.7M-11.9%
NEA BAPTIST MEMORIAL HOSPITALAR180$246.7M1.0%
CONWAY REGIONAL MEDICAL CENTERAR169$232.9M-14.5%
ARKANSAS HEART HOSPITALAR112$205.9M1.2%
NATIONAL PARK MEDICAL CENTERAR126$118.8M2.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $7.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.0M+210bp18mo
Cost to Collect4.5%2.5%$1.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.2M+122bp9mo
Clean Claim Rate88.0%96.0%$61K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.0M
Cost to Collect
$1.9M
Denial Rate Reduction
$1.9M
A/R Days Reduction
$1.2M
Clean Claim Rate
$61K
Total EBITDA Uplift$7.0M
Current EBITDA$-14.8M
+ RCM Uplift+$7.0M
Pro Forma EBITDA$-7.8M
Current Margin-15.6%
Pro Forma Margin-8.2%
WC Released (1x)$3.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-22.7M$-27.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-22.7M$-37.7M0.00x-100.0%
Bull Case9.0x11.0x$-20.4M$-22.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-20.4M$-30.1M0.00x-100.0%
Bear Case11.0x10.0x$-25.0M$-55.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-25.0M$-68.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 50.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 31 hospitals with 54-216 beds
  • Same-state prioritization (n=32)
  • Comp margins: P25=-11.8% / P50=1.0% / P75=6.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.